Moe Matsuzawa

Publications : 0
Aldex : 0
H-index : 0
Citations : 0


The protective role of conjunctival goblet cell mucin sialylation.

Moe Matsuzawa, Jiro Kitaura et 19 al.

Mar 17, 2023 in Nature communications
Gel-forming mucins secreted by conjunctival goblet cells have been implicated in the clearance of allergens, pathogens, and debris. However, their roles remain incompletely understood. Here we show that human and mouse conjunctival goblet cell mucins have Alcian blue-detectable sialic acids, but not sulfates in the steady state. Interestingly, Balb/c mouse strain lacks this sialylation due to a po...


Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study.

Shuta Kishishita et 6 al.

Nov 30, 2022 in BMC ophthalmology
Macular edema is found in more than half of branch retinal vein occlusion (BRVO) cases, leading to visual loss in most of these cases. Intravitreal injection of anti-vascular endothelial growth factor is currently the standard treatment for macular edema due to BRVO (BRVO-ME). The difference in the effects of aflibercept and ranibizumab on the choroid in BRVO-ME is unknown. Therefore, we analyzed ...


Pollen shells and soluble factors play non-redundant roles in the development of allergic conjunctivitis in mice.

Saaya Fukase, Jiro Kitaura et 17 al.

Aug 21, 2021 in The ocular surface
We aimed to clarify the role of particulate allergen exposure to the conjunctiva in the development of allergic conjunctivitis. We administered ragweed pollen suspension, pollen extract, pollen shell, particulate air pollutants, and their combinations to the mouse conjunctiva five days a week without prior sensitization. Clinical signs were scored. Histological changes, cellular infiltrations, mRN...


Identification of inhibitory mechanisms in pseudo-allergy involving Mrgprb2/MRGPRX2-mediated mast cell activation

Ayako Takamori, Jiro Kitaura et 25 al.

Nov 1, 2018 in Journal of Allergy and Clinical Immunology
Ceramide-CD300f binding inhibits mouse Mrgprb2 (human MrgprX2)-mediated mast cell activation, thereby suppressing pseudo-allergic reactions. CD300f could be a therapeutic target against IgE-independent pseudo-allergy as well as IgE-dependent allergy.